Maravai Lifesciences Net Worth
Maravai Lifesciences Net Worth Breakdown | MRVI |
Maravai Lifesciences Net Worth Analysis
Maravai Lifesciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Maravai Lifesciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Maravai Lifesciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Maravai Lifesciences' net worth analysis. One common approach is to calculate Maravai Lifesciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Maravai Lifesciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Maravai Lifesciences' net worth. This approach calculates the present value of Maravai Lifesciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Maravai Lifesciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Maravai Lifesciences' net worth. This involves comparing Maravai Lifesciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Maravai Lifesciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Maravai Lifesciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Maravai Lifesciences' net worth research are outlined below:
| Maravai Lifesciences generated a negative expected return over the last 90 days | |
| Maravai Lifesciences has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 259.19 M. Net Loss for the year was (259.62 M) with profit before overhead, payroll, taxes, and interest of 108.31 M. | |
| Maravai Lifesciences has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: ROSEN, A TOP RANKED LAW FIRM, Encourages Maravai Lifesciences Holdings, Inc. ... |
Maravai Lifesciences Quarterly Good Will |
|
Maravai Lifesciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Maravai Lifesciences Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Maravai Lifesciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Maravai Lifesciences Target Price Consensus
Maravai target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Maravai Lifesciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 16 | Buy |
Most Maravai analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Maravai stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Maravai Lifesciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMaravai Lifesciences Target Price Projection
Maravai Lifesciences' current and average target prices are 2.24 and 9.07, respectively. The current price of Maravai Lifesciences is the price at which Maravai Lifesciences Holdings is currently trading. On the other hand, Maravai Lifesciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Maravai Lifesciences Market Quote on 25th of March 2025
Target Price
Analyst Consensus On Maravai Lifesciences Target Price
Know Maravai Lifesciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Maravai Lifesciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Maravai Lifesciences Holdings backward and forwards among themselves. Maravai Lifesciences' institutional investor refers to the entity that pools money to purchase Maravai Lifesciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jennison Associates Llc | 2024-12-31 | 3 M | Geode Capital Management, Llc | 2024-12-31 | 2.8 M | State Street Corp | 2024-12-31 | 2.8 M | Marshall Wace Asset Management Ltd | 2024-12-31 | 2.8 M | Glenmede Trust Co Na | 2024-12-31 | 2.2 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.2 M | Bamco Inc | 2024-12-31 | 2.2 M | Fmr Inc | 2024-12-31 | 2.1 M | Ubs Group Ag | 2024-12-31 | 2 M | Gtcr Llc | 2024-12-31 | 20.2 M | Mackenzie Investments | 2024-12-31 | 12.4 M |
Follow Maravai Lifesciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 569.71 M.Market Cap |
|
Project Maravai Lifesciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.22) | (0.21) | |
| Return On Capital Employed | (0.25) | (0.24) | |
| Return On Assets | (0.14) | (0.14) | |
| Return On Equity | (0.45) | (0.42) |
When accessing Maravai Lifesciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Maravai Lifesciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Maravai Lifesciences' profitability and make more informed investment decisions.
Evaluate Maravai Lifesciences' management efficiency
Maravai Lifesciences has return on total asset (ROA) of (0.0364) % which means that it has lost $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3798) %, meaning that it created substantial loss on money invested by shareholders. Maravai Lifesciences' management efficiency ratios could be used to measure how well Maravai Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. The Maravai Lifesciences' current Return On Tangible Assets is estimated to increase to -0.21. The Maravai Lifesciences' current Return On Capital Employed is estimated to increase to -0.24. As of now, Maravai Lifesciences' Non Currrent Assets Other are increasing as compared to previous years. The Maravai Lifesciences' current Other Assets is estimated to increase to about 973.4 M, while Other Current Assets are projected to decrease to under 15.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.19 | 3.04 | |
| Tangible Book Value Per Share | 1.61 | 1.69 | |
| Enterprise Value Over EBITDA | (2.97) | (2.82) | |
| Price Book Value Ratio | 2.31 | 2.19 | |
| Enterprise Value Multiple | (2.97) | (2.82) | |
| Price Fair Value | 2.31 | 2.19 | |
| Enterprise Value | 2.1 B | 3.1 B |
The leadership approach at Maravai Lifesciences' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Enterprise Value Revenue 1.451 | Revenue | Quarterly Revenue Growth (0.24) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Maravai Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Maravai Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Maravai Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Maravai Lifesciences Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 4th of March 2025 Other Reports | ViewVerify | |
| 28th of January 2025 Other Reports | ViewVerify |
Maravai Lifesciences Earnings per Share Projection vs Actual
Maravai Lifesciences Corporate Management
| Kurt Oreshack | General VP | Profile | |
| Christine Dolan | Executive Technologies | Profile | |
| Brian Neel | Chief Production | Profile | |
| Peter Leddy | Executive Officer | Profile | |
| Christopher Benoit | Executive Enzymes | Profile | |
| Becky Buzzeo | Executive Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Earnings Share (1.05) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets |
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.